Compare LYFT Inc (LYFT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Sanofi SA — how do they compare? LYFT Inc trades at $15.51 (market cap $5.86B), while Sanofi SA trades at $44.09 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 17.9× LYFT Inc's market cap, and Sanofi SA pays a 5.5% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| LYFT | SNY | |
|---|---|---|
Market Cap | $5.86B | $104.83B |
Sector | Industrials | Health |
52-Week High | $24.57 | $52.34 |
52-Week Low | $12.65 | $41.33 |
Enterprise Value | $5.39B | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.39, down 0.84% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company demonstrates strong revenue growth, reaching $6.32B in 2025 with a remarkable net income margin of 43.82%, though recent quarterly EPS results have been inconsistent with two misses and one beat. Analyst consensus leans neutral with 57.6% hold ratings but offers a $17.86 price target suggesting 16% upside potential.
Lyft presents a compelling valuation case with a low P/E of 2.27 and P/S of 0.98, supported by improving cash flow trends and strategic expansions into new markets. However, risks include competitive pressure from Uber, inconsistent earnings performance, and regulatory scrutiny over pricing practices. The upcoming Q2 2026 earnings report on August 6 will be critical for validating the company's growth trajectory.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
